PDCD1 and neoplasm: However, the combination of 10 3′-UTR ZIKV with anti–PD-1 prolonged median survival to 33.5 days after tumor implantation, and the survivor rate increased from 0% to approximately 40% in the combination treatment group (Figure 5D).